drug
as of 2026-07-01ondansetron
Ondansetron
MeSH D017294
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Pakistan Institute of Living and Learning
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
5
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
NCT01121042Phase 3Completed
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
NCT02614586Phase 1Terminated
Randomized Double Blind Placebo Control Study in Patients with Schizophrenia
NCT01602029Phase 2Completed
Role of Anti-Inflammatory Agents in Patients With Schizophrenia
NCT00929955Phase 1Completed
5HT3 Antagonism and Auditory Gating in Schizophrenia
NCT00018850—Completed
KOLs & investigators
2
Professor Jayashri KulkarniKOL score 6
Prof Imran B Chaudhry, MDKOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
trial
indication
indication
indication
indication
KOL
Professor Jayashri Kulkarni
personKOL score 6
Prof Imran B Chaudhry, MD
personKOL score 5